Geert A. Cirkel

1.7k total citations
29 papers, 576 citations indexed

About

Geert A. Cirkel is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Geert A. Cirkel has authored 29 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Geert A. Cirkel's work include Cancer Genomics and Diagnostics (11 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Renal cell carcinoma treatment (5 papers). Geert A. Cirkel is often cited by papers focused on Cancer Genomics and Diagnostics (11 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Renal cell carcinoma treatment (5 papers). Geert A. Cirkel collaborates with scholars based in Netherlands, United States and Germany. Geert A. Cirkel's co-authors include Emile E. Voest, Martijn P. Lolkema, Stefan Sleijfer, Jan H.M. Schellens, Jeanine M.L. Roodhart, Neeltje Steeghs, Marc G. Besselink, Alwin D. R. Huitema, Hjalmar C. van Santvoort and Laura G.M. Daenen and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Geert A. Cirkel

26 papers receiving 563 citations

Peers

Countries citing papers authored by Geert A. Cirkel

Since Specialization

Citations

This map shows the geographic impact of Geert A. Cirkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geert A. Cirkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geert A. Cirkel more than expected).

Fields of papers citing papers by Geert A. Cirkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geert A. Cirkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geert A. Cirkel. The network helps show where Geert A. Cirkel may publish in the future.

Co-authorship network of co-authors of Geert A. Cirkel

This figure shows the co-authorship network connecting the top 25 collaborators of Geert A. Cirkel. A scholar is included among the top collaborators of Geert A. Cirkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geert A. Cirkel. Geert A. Cirkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study 2025 ·EClinicalMedicine ·(unknown), Pauline A. J. Vissers, Mirjam A. G. Sprangers, (unknown), (unknown), Lydia G. van der Geest, Geert A. Cirkel, Judith de Vos‐Geelen, Marjolein Y.V. Homs, G.J. Creemers, Martijn W.J. Stommel, Lois A. Daamen, Marc G. Besselink, Johanna W. Wilmink, Hanneke W.M. van Laarhoven	0
2	Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response 2024 ·Journal of Experimental & Clinical Cancer Research ·(unknown), G. Emerens Wensink, Carla S. Veríssimo, Esmee Koedoot, (unknown), (unknown), (unknown), (unknown), (unknown), Geert A. Cirkel, (unknown), René Overmeer, Miriam Koopman, Manon N.G.J.A. Braat, (unknown), Sjoerd G. Elias, Robert G. Vries, Onno Kranenburg, Sylvia F. Boj, Jeanine M.L. Roodhart	26
3	Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort. 2023 ·Journal of Clinical Oncology ·Lorenzo Pilla, (unknown), Kathrin Heinrich, Volker Kunzmann, Alice Boilève, Geert A. Cirkel, Sara Lonardi, Benoist Chibaudel, Anthony Turpin, (unknown), Vincent Hautefeuille, Caterina Vivaldi, Thibault Mazard, (unknown), Monica Niger, Gerald W. Prager, Clélia Coutzac, (unknown), Édouard Auclin, Julien Taı̈eb	0
4	Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort 2023 ·European Journal of Cancer ·Julien Taı̈eb, (unknown), Kathrin Heinrich, Volker Kunzmann, Alice Boilève, Geert A. Cirkel, Sara Lonardi, Benoist Chibaudel, Anthony Turpin, (unknown), Vincent Hautefeuille, Caterina Vivaldi, Thibault Mazard, (unknown), Monica Niger, Gerald W. Prager, Clélia Coutzac, C. Benedikt Westphalen, Édouard Auclin, Lorenzo Pilla	44
5	Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study 2023 ·Cancers ·(unknown), Hanneke W.M. van Laarhoven, Geert A. Cirkel, Jan Willem B. de Groot, Bas Groot Koerkamp, Teresa Macarulla, Davide Melisi, Eileen M. O’Reilly, Hjalmar C. van Santvoort, Tara M. Mackay, Marc G. Besselink, Johanna W. Wilmink	2
6	Systemic anticancer treatment in the Netherlands: Few hospitals treat many patients, many hospitals treat few patients 2023 ·Health Policy ·(unknown), Rick A. Vreman, Geert A. Cirkel, Marie José Kersten, Hanneke W.M. van Laarhoven, Lonneke Timmers	0
7	A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE) 2022 ·Trials ·(unknown), Lois A. Daamen, Marc G. Besselink, A. Bruynzeel, Olivier R. Busch, Geert A. Cirkel, Bas Groot Koerkamp, (unknown), H.D. Heerkens, Hanneke W.M. van Laarhoven, Gert J. Meijer, Joost J. Nuyttens, Hjalmar C. van Santvoort, Geertjan van Tienhoven, Helena M. Verkooijen, Johanna W. Wilmink, I. Quintus Molenaar, Martijn Intven, (unknown)	4
8	Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study 2022 ·Frontiers in Oncology ·(unknown), Melinda S. Schuurman, Dorothea Wagner, Judith de Vos‐Geelen, Lydia G. van der Geest, Jan‐Willem B. de Groot, Bas Groot Koerkamp, Ignace H. J. T. de Hingh, Marjolein Y.V. Homs, Geert‐Jan Creemers, Geert A. Cirkel, Hjalmar C. van Santvoort, Olivier R. Busch, Marc G. Besselink, Casper H.J. van Eijck, Johanna W. Wilmink, Hanneke W. M. van Laarhoven	14
9	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features 2021 ·Nature Communications ·(unknown), Marcel Smid, Job van Riet, Lindsay Angus, Mariëtte Labots, Neeltje Steeghs, Mathijs P. Hendriks, Geert A. Cirkel, Johan M. van Rooijen, Albert J. ten Tije, Martijn P. Lolkema, Edwin Cuppen, Stefan Sleijfer, John W.M. Martens, Saskia M. Wilting	45
10	Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features 2021 ·Nature Communications ·(unknown), Marcel Smid, Job van Riet, Lindsay Angus, Mariëtte Labots, Neeltje Steeghs, Mathijs P. Hendriks, Geert A. Cirkel, Johan M. van Rooijen, Albert J. ten Tije, Martijn P. Lolkema, Edwin Cuppen, Stefan Sleijfer, John W.M. Martens, Saskia M. Wilting	6
11	Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids 2018 ·Cancer Chemotherapy and Pharmacology ·Daphne van der Velden, Geert A. Cirkel, Julia M. Houthuijzen, Erik van Werkhoven, Jeanine M.L. Roodhart, Laura G.M. Daenen, Sovann Kaing, Johan Gerrits, Nanda M. Verhoeven‐Duif, Cecile Grootscholten, Henk Boot, (unknown), Haiko J. Bloemendal, Filip De Vos, Emile E. Voest	7
12	Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer 2016 ·JAMA Oncology ·Geert A. Cirkel, Paul Hamberg, Stefan Sleijfer, O. J. L. Loosveld, M. Wouter Dercksen, Maartje Los, Marco B. Polée, Franchette van den Berkmortel, Maureen J.B. Aarts, Laurens V. Beerepoot, Gerard Groenewegen, Martijn P. Lolkema, Metin Tascilar, Johanneke E.A. Portielje, Frank Peters, Heinz‐Josef Klümpen, Vincent van der Noort, John B.A.G. Haanen, Emile E. Voest	25
13	A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial). 2016 ·Journal of Clinical Oncology ·Geert A. Cirkel, Paul Hamberg, Stefan Sleijfer, O. J. L. Loosveld, Wouter Dercksen, Maartje Los, John B.A.G. Haanen, Marco B. Polée, Franchette van den Berkmortel, Maureen J.B. Aarts, Laurens V. Beerepoot, Gerard Groenewegen, Martijn P. Lolkema, Metin Tascilar, (unknown), Frank Peters, Heinz‐Josef Klümpen, (unknown), Emile E. Voest	1
14	A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies 2016 ·Investigational New Drugs ·Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte, Annegret Van der Aa, Giocondo Lorenzon, Florence Namour, Philippe Pujuguet, (unknown), (unknown), Tom J. Snijders, Emile E. Voest, Jan H.M. Schellens, Martijn P. Lolkema	53
15	Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours 2014 ·British Journal of Cancer ·Nienke A. G. Lankheet, Jacqueline S. L. Kloth, Christa G.M. Gadellaa-van Hooijdonk, Geert A. Cirkel, Ron H.J. Mathijssen, Martijn P. Lolkema, Jan H.M. Schellens, Emile E. Voest, Stefan Sleijfer, Maja J.A. de Jonge, John B.A.G. Haanen, Jos H. Beijnen, Alwin D. R. Huitema, Neeltje Steeghs	88
16	Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies 2013 ·Oncogene ·Laura G.M. Daenen, Julia M. Houthuijzen, Geert A. Cirkel, Jeanine M.L. Roodhart, Yuval Shaked, Emile E. Voest	30
17	Genomic and transcriptomic plasticity in treatment-naïve ovarian cancer 2013 ·Genome Research ·Marlous Hoogstraat, Mirjam S. de Pagter, Geert A. Cirkel, Markus J. van Roosmalen, Timothy T. Harkins, Karen Duran, (unknown), Ivo Renkens, Petronella O. Witteveen, Clarence Lee, Isaäc J. Nijman, (unknown), Ruben van ‘t Slot, Trudy N. Jonges, Martijn P. Lolkema, Marco J. Koudijs, Ronald P. Zweemer, Emile E. Voest, Edwin Cuppen, Wigard P. Kloosterman	63
18	Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors. 2012 ·Journal of Clinical Oncology ·Nienke A. G. Lankheet, Jacqueline S. L. Kloth, Christa G.M. Gadellaa-van Hooijdonk, Geert A. Cirkel, Ron H.J. Mathijssen, Martijn P. Lolkema, Jan H.M. Schellens, Emile E. Voest, Stefan Sleijfer, Jos H. Beijnen, Alwin D. R. Huitema, Neeltje Steeghs	5
19	Acute chest pain caused by pericardial fat necrosis 2010 ·Thorax ·Daniël A. F. van den Heuvel, H. Wouter van Es, Geert A. Cirkel, Willem Jan W. Bos	12
20	End‐tidal carbon monoxide measurements in infant respiratory distress syndrome 2006 ·Acta Paediatrica ·Tannette G. Krediet, Geert A. Cirkel, Hendrik J. Vreman, Ronald J. Wong, David K. Stevenson, Floris Groenendaal, Johannes Egberts, Frank van Bel	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact